Adicet Bio Inc ACET:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/17/24 EDT
1.60UNCH (UNCH)
Volume
10,391
Close
1.60quote price arrow up+0.03 (+1.91%)
Volume
1,044,185
52 week range
1.10 - 6.65
Loading...
  • Open1.58
  • Day High1.68
  • Day Low1.58
  • Prev Close1.57
  • 52 Week High6.65
  • 52 Week High Date05/23/23
  • 52 Week Low1.10
  • 52 Week Low Date11/29/23

Key Stats

  • Market Cap131.478M
  • Shares Out82.17M
  • 10 Day Average Volume1.76M
  • Dividend-
  • Dividend Yield-
  • Beta1.97
  • YTD % Change-15.34

KEY STATS

  • Open1.58
  • Day High1.68
  • Day Low1.58
  • Prev Close1.57
  • 52 Week High6.65
  • 52 Week High Date05/23/23
  • 52 Week Low1.10
  • 52 Week Low Date11/29/23
  • Market Cap131.478M
  • Shares Out82.17M
  • 10 Day Average Volume1.76M
  • Dividend-
  • Dividend Yield-
  • Beta1.97
  • YTD % Change-15.34

RATIOS/PROFITABILITY

  • EPS (TTM)-2.95
  • P/E (TTM)-0.54
  • Fwd P/E (NTM)-1.05
  • EBITDA (TTM)-123.572M
  • ROE (TTM)-53.25%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-279.28%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/07/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Adicet Bio Inc

 

Profile

MORE
Adicet Bio, Inc. is a clinical stage biotechnology company. The Company is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell...
Carl Gordon Ph.D.
Non-Executive Chairman of the Board, Independent Director
Chen Schor CPA
President, Chief Executive Officer, Director
Nick Harvey
Chief Financial Officer
Don Healey Ph.D.
Chief Technology Officer
Address
200 BERKELEY STREET, 19TH FLOOR
Boston, MA
02116
United States

Top Peers

SYMBOLLASTCHG%CHG
RZLT
Rezolute Inc
2.64+0.08+3.12%
VIGL
Vigil Neuroscience Inc
3.52-0.02-0.56%
NVCT
Nuvectis Pharma Inc
6.15-0.38-5.82%
VTGN
Vistagen Therapeutics Inc
4.44-0.11-2.42%
VOR
Vor Biopharma Inc
1.81+0.01+0.56%